title: Resistance of nitrogen metabolism to growth hormone treatment in the early phase after injury of patients with multiple injuries.
abstract: OBJECTIVE
  Several studies have shown an anticatabolic effect of recombinant human growth hormone (rhGH) in surgical patients. We investigated, in a prospective, randomized, double blind, and placebo-controlled study, the effect of r-hGH on hormone and nitrogen metabolism in 14 patients with multiple injuries in the early phase of injury.
  
  
  METHODS
  All patients were treated in the intensive care unit, had mechanical ventilation, and were highly catabolic, with a mean daily nitrogen loss of 13.2 +/- 1.8 g. r-hGH was given subcutaneously (once a day, at 8 PM) in a dosage of 0.2 IU/kg.d for seven days, starting on the second day after injury.
  
  
  RESULTS
  Administration of r-hGH evoked a significant increase in plasma concentrations of GH, insulin-like growth factor-I (IGF-I), and insulin-like growth factor binding-protein-3 (IGFBP-3). No significant differences were found for either daily or cumulative nitrogen balances (-103.1 +/- 14 g for patients receiving r-hGH and -92.1 +/- 18.1 for those with placebo). r-hGH therapy did not affect skeletal muscle extracellular water, nor did it affect plasma or muscle concentrations of total free amino acids or glutamine. Plasma albumin, prealbumin, and retinol-binding protein concentrations were also unchanged by r-hGH therapy, as were the urinary excretion of potassium and urea.
  
  
  CONCLUSIONS
  We conclude that elevated plasma levels of GH, insulin, and IGF-I are unable to effect a protein anabolic drive in patients with multiple injuries during the early postinjury phase and assume that this r-hGH resistance to nitrogen metabolism takes place at the level distal to IGF-I.
authors.affiliation: Surgical Department, University of Vienna, Austria.
authors.forename: E
authors.initials: E
authors.lastname: Roth
authors.forename: L
authors.initials: L
authors.lastname: Valentini
authors.forename: M
authors.initials: M
authors.lastname: Semsroth
authors.forename: T
authors.initials: T
authors.lastname: Hölzenbein
authors.forename: S
authors.initials: S
authors.lastname: Winkler
authors.forename: W F
authors.initials: WF
authors.lastname: Blum
authors.forename: M B
authors.initials: MB
authors.lastname: Ranke
authors.forename: M
authors.initials: M
authors.lastname: Schemper
authors.forename: A
authors.initials: A
authors.lastname: Hammerle
authors.forename: J
authors.initials: J
authors.lastname: Karner
mesh_terms: D000328:Adult; D000596:Amino Acids / Q000378:metabolism; D002352:Carrier Proteins / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D013006:Growth Hormone / Q000097:blood / Q000627:therapeutic use*; D006131:Growth Inhibitors / Q000097:blood; D006801:Humans; D007328:Insulin / Q000097:blood; D018969:Insulin-Like Growth Factor Binding Proteins; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008297:Male; D009104:Multiple Trauma / Q000097:blood / Q000378:metabolism*; D018482:Muscle, Skeletal / Q000737:chemistry; D009584:Nitrogen / Q000378:metabolism*; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D000596:Amino Acids; D002352:Carrier Proteins; D006131:Growth Inhibitors; D007328:Insulin; D018969:Insulin-Like Growth Factor Binding Proteins; D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D009584:Nitrogen